Halozyme Therapeutics HALO Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's deferred tax assets?
- Halozyme Therapeutics (HALO) reported deferred tax assets of $47.53M in Q1 2026.
- How has Halozyme Therapeutics's deferred tax assets changed year-over-year?
- Halozyme Therapeutics's deferred tax assets increased by 815.8% year-over-year, from $5.19M to $47.53M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.